

WHEN BLEEDS HAPPEN

Will you be prepared?

Barbara lives with Factor VII deficiency and uses NovoSeven® RT

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia with a decreased or absent response to platelet transfusions
- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

- **Serious blood clots** that form in veins and arteries with the use of NovoSeven® RT have been reported



Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)





About Factor VII deficiency (FVIIId)

FVIIId is a rare bleeding disorder in which there are low levels of factor VII in the blood. Factor VII plays an important role in the blood-clotting process. When there is not enough factor VII in the blood, clotting can take much longer than normal or may not occur at all. Mild-to-moderate FVIIId is marked by increased bleeding after surgery and trauma, while severe FVIIId is marked by spontaneous, severe, and even life-threatening bleeding.

FVIIId is rare, affecting an estimated 1 in every 500,000 people. It is inherited when children receive an abnormal gene from both parents. Men and women have an equal chance of being born with FVIIId.

FVIIId can be detected at birth. However, some people with FVIIId grow into adulthood without knowing they have it. The blood test that confirms congenital factor VII deficiency is called a clotting assay. It measures the amount of time it takes to create a clot.

70% of patients with joint bleeds were less than 5 years of age, so early treatment with the right therapy is critical.

Common signs and symptoms of FVIIId

The most common signs of FVIIId, other than excessive bleeding after injury or invasive procedures, include:

- Nosebleeds
- Easy bruising
- Bleeding from the gums
- Heavy or prolonged menstrual bleeding
- Head bleeds in newborns
- Heavy bleeding following circumcision

▶ **Scan the QR code to learn more about bleed identification and management.**



It's important to have an on-demand treatment with you to stop bleeds whenever and wherever they happen.

Xavier lives with Factor VII deficiency and uses NovoSeven® RT



The one and only **NovoSeven® RT**
The Recombinant Factor VIIa (rFVIIa)
TRUSTED BY PATIENTS FOR OVER 30 YEARS^a

FIRST rFVIIa approved for:
Factor VII deficiency
&
ONLY rFVIIa approved for:

- All ages (children, adolescents, and adults)
- Before, during, and after surgery

Over **70** FVIId patients and **124** FVIId bleeds have been treated in clinical trials and registry data^b

Recombinant activated FVII (rFVIIa) is recommended by MASAC for FVIId.

MASAC=Medical and Scientific Advisory Council.

^aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

^bIn clinical trials and data collected from registries, NovoSeven® RT was studied in people with hemophilia A or B with inhibitors, Glanzmann's thrombasthenia, congenital FVIId, and acquired hemophilia.

Important Safety Information (cont'd)

What is the most important information I should know about NovoSeven® RT? (cont'd)

- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)




Taylor

lives with Factor VII deficiency and uses NovoSeven® RT




Get fast bleed control—whenever and wherever they happen



In treating bleeds in Factor VII deficiency

NovoSeven® RT is **proven effective** to treat factor VII deficiency (FVIIId) **at home** and was 93% effective at stopping nonsurgical and surgical bleeds in people with FVIIId.^a



In controlling bleeds

90% efficacy in bleed control in trial patients for 43 bleeding episodes and 26 surgeries.

^aFrom an analysis of published cases and people (N=70) who took part in trials and registries for 124 bleeding episodes, surgeries, or prophylaxis regimens.

Important Safety Information (cont'd)

What is the most important information I should know about NovoSeven® RT? (cont'd)

- You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>



The **one** and **only** NovoSeven® RT

NovoSeven® RT is the **only** recombinant therapy indicated for Factor VII deficiency

Established safety profile that comes with experience^a

- Low 0.82% rate of unintended blood clots reported in clinical trials and post-marketing surveillance registries
 - Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
- Recombinant manufacturing minimizes the possibility of viral contamination
 - Made without any human blood or plasma

Proven **effective** to treat FVIIId at home

^aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999 for CHWI and FVIIId.

Important Safety Information (cont'd)

What should I tell my healthcare provider before using NovoSeven® RT?

- Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
 - congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
 - are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
 - history of heart or blood vessel diseases



Effective in surgeries and procedures

NovoSeven® RT is approved by the FDA for treating people with Factor VII deficiency before, during, and after surgery and procedures.

NovoSeven® RT was **proven to effectively control bleeds throughout the surgery process.**



Barbara lives with Factor VII deficiency and uses NovoSeven® RT

Talk with your doctor for more information about controlling bleeds during and after surgery or a procedure.

Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)



Xavier

lives with Factor VII deficiency and uses NovoSeven® RT



Experience **fast bleed control** with NovoSeven® RT

Fast to infuse

Fast infusions mean that NovoSeven® RT gets to work stopping bleeds quickly.

NovoSeven® RT
(15-30 mcg/kg)



- NovoSeven® RT is given as an intravenous (IV) bolus injection **over 2-5 minutes**, depending on the dose administered
- NovoSeven® RT can be redosed every 4-6 hours, which lets you dose as needed to get bleeds under control fast
- NovoSeven® RT is room temperature stable up to 77 °F so you can be on the go^a
- Your hemophilia treatment center (HTC) and your doctor will help you decide which dosing schedule is best for you

^aNovoSeven® RT should be stored between 36 °F and 77 °F.

Important Safety Information (cont'd)

What should I tell my healthcare provider before using NovoSeven® RT? (cont'd)

- Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)



Simple dosing means **more time** for you.

Available in 4 different vial sizes to meet your needs



Simple dosing delivers the results you need

15-30 mcg/kg

- **NovoSeven® RT can be redosed every 4-6 hours**, which lets you dose as needed to get bleeds under control fast
- **No daily dose restrictions**

With MixPro®, preparing a dose is as easy as

ATTACH, TWIST, AND MIX^a

- Fast to mix, fast to infuse, and fast to control bleeds

Scan to watch the video and see how to prepare a dose with MixPro®



Small, compact size lets NovoSeven® RT go with you^b



^aPlease see Instructions for Use for complete instructions on preparing a dose.

^bNovoSeven® RT should be stored between 36 °F and 77 °F.

Important Safety Information (cont'd)

What are the possible side effects of NovoSeven® RT?

- The most common and serious side effects are blood clots
- Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please see Important Safety Information throughout.
Please see Prescribing Information at <https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)



Trusted to stop bleeds **for over 30 years^a**

FIRST rFVIIa approved for:
Factor VII deficiency
&
ONLY rFVIIa approved for:

- All ages (children, adolescents, and adults)
- Before, during, and after surgery

- ✓ **70 FVIIId patients and 124 FVIIId bleeds treated in clinical trials and registry data**
- ✓ **Proven control of the mildest to the most life-threatening bleeds**
- ✓ **Fast bleed control for all ages**
- ✓ **Proven effective to treat FVIIId at home**

Taylor

lives with Factor VII deficiency and uses NovoSeven[®] RT



^aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

Important Safety Information (*cont'd*)

What is the most important information I should know about NovoSeven[®] RT?

NovoSeven[®] RT may cause serious side effects, including:

- **Serious blood clots** that form in veins and arteries with the use of NovoSeven[®] RT have been reported
- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven[®] RT

Please see Important Safety Information throughout.

Please see Prescribing Information at

<https://www.novo-pi.com/novosevenrt.pdf>

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

MixPro[®] and NovoSeven[®] are registered trademarks of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

© 2022 Novo Nordisk Printed in the U.S.A.

US22NSVN00104 December 2022



NovoSeven[®] RT
Coagulation Factor VIIa
(Recombinant)

